Table 3.
Clinical trial | AZA protocol | Event | Frequency (n) |
---|---|---|---|
AZA in combination with thalidomide in MDS17 | 75 mg/m2 for 5 days every 28 days | Pericarditis atrial fibrillation | 2% (1) 5% (2) |
Phase II, 3 alternative dosing schedules of AZA in MDS8 | 75 or 50 mg/m2 with various time intervals | Congestive heart failure | 3% (5) |
Phase II, addition of AZA to standard chemotherapy in older patients with AML14 | 75 mg/m2 for 5 days every 28 days | Recruitment halted due to increased rate of cardiac toxicity in the experimental arm | No details |
Phase I, lenalidomide and AZA in high‐risk MDS18 | 75 or 50 mg/m2 with various time intervals | Atrial fibrillation grade 3 or 4 | 3% (1) |
Phase II, AZA and lenalidomide in with higher‐risk MDS7 | 75 mg/m2 for 5 days every 28 days | Congestive heart failure, arrhythmia, vasovagal episode | 11% (4) |
Phase II, prophylactic AZA and donor lymphocyte infusion following allogenic hematopoietic stem cell transplantation for high‐risk AML and MDS9 | 32 mg/m2 for 5 days every 28 days | Sudden death due to heart failure | 3% (1) |
MDS, myelodysplastic syndrome; AML, acute myeloid leukaemia